Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease

Respirology

Volumn 20, Issue 1, 2015, Pages 101-107

  Ingebrigtsen, Truls S ^a,b,c   Marott, Jacob L ^b   Vestbo, Jørgen ^a,b,d   Nordestgaard, Børge G ^b,c,e   Hallas, Jesper ^f   Lange, Peter ^b,c,d,g  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Copenhagen General Population Study University of Copenhagen ^*  (Denmark)

^f HVIDOVRE HOSPITAL   (Denmark)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

acid inhibitory treatment; chronic obstructive pulmonary disease; reflux

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; ANTACID AGENT; ANTIINFECTIVE AGENT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DYSPNEA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; INJURY SEVERITY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PROPORTIONAL HAZARDS MODEL; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; RISK FACTOR; COMPLICATION; DENMARK; DISEASE COURSE; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

AGED; ANTACIDS; ANTI-BACTERIAL AGENTS; DENMARK; DISEASE PROGRESSION; FEMALE; GASTROESOPHAGEAL REFLUX; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84918510511     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12420     Document Type: Article

References (41)

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S,. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397-412.
2. Pauwels RA, Rabe KF,. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620.
3. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et-al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347-365.
4. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et-al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128-1138.
5. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S,. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143: 317-326.
6. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM, POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093-1103.
7. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG,. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012; 186: 975-981.
8. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG,. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309: 2353-2361.
9. Pacheco-Galvan A, Hart SP, Morice AH,. Relationship between gastro-oesophageal reflux and airway diseases: the airway reflux paradigm. Arch. Bronconeumol. 2011; 47: 195-203.
10. Kim J, Lee JH, Kim Y, Kim K, Oh YM, Yoo KH, Rhee CK, Yoon HK, Kim YS, Park YB, et-al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm. Med. 2013; 13: 51.
11. Liang B, Wang M, Yi Q, Feng Y,. Association of gastroesophageal reflux disease risk with exacerbations of chronic obstructive pulmonary disease. Dis. Esophagus 2013; 26: 557-560.
12. Sakae TM, Pizzichini MM, Teixeira PJ, Silva RM, Trevisol DJ, Pizzichini E,. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J. Bras. Pneumol. 2013; 39: 259-271.
13. Rogha M, Behravesh B, Pourmoghaddas Z,. Association of gastroesophageal reflux disease symptoms with exacerbations of chronic obstructive pulmonary disease. J. Gastrointestin. Liver Dis. 2010; 19: 253-256.
14. Takada K, Matsumoto S, Kojima E, Iwata S, Okachi S, Ninomiya K, Morioka H, Tanaka K, Enomoto Y,. Prospective evaluation of the relationship between acute exacerbations of COPD and gastroesophageal reflux disease diagnosed by questionnaire. Respir. Med. 2011; 105: 1531-1536.
15. Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S, Kinose D, Oqawa E, Hoshino Y, Niimi A, et-al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008; 63: 951-955.
16. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M,. The Copenhagen City Heart Study-Østerbroundersøgelsen. Tables with data from the third examination 1991-1994. Eur. Heart J. 2001; 3: H1-H83.
17. Andersen LI, Madsen PV, Dalgaard P, Jensen G,. Validity of clinical symptoms in benign esophageal disease, assessed by questionnaire. Acta Med. Scand. 1987; 221: 171-177.
18. Gaist D, Sorensen HT, Hallas J,. The Danish prescription registries. Dan. Med. Bull. 1997; 44: 445-448.
19. Ingebrigtsen TS, Marott JL, Vestbo J, Hallas J, Nordestgaard BG, Dahl M, Lange P,. Characteristics of undertreatment in COPD in the general population. Chest 2013; 144: 1811-1818.
20. The Comprehensive R Archive Network (CRAN). The Comprehensive R Archive Network (CRAN) Homepage 2014. [Accessed 29 Sep 2014.] Available from URL: http://cran.r-project.org/
21. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2013. [Accessed 29 Sep 2014.] Available from URL: http://www.R-project.org/
22. Crawley M,. The R Book. Imperial College London at Silwood Park. John Wiley & Sons, Ltd., London, UK, 2007.
23. Eryuksel E, Dogan M, Olgun S, Kocak I, Celikel T,. Incidence and treatment results of laryngopharyngeal reflux in chronic obstructive pulmonary disease. Eur. Arch. Otorhinolaryngol 2009; 266: 1267-1271.
24. Mokhlesi B, Morris AL, Huang CF, Curcio AJ, Barrett TA, Kamp DW,. Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest 2001; 119: 1043-1048.
25. Corley DA, Kubo A,. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2006; 101: 2619-2628.
26. Shrank WH, Patrick AR, Brookhart MA,. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J. Gen. Intern. Med. 2011; 26: 546-550.
27. Huang JQ, Sridhar S, Hunt RH,. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
28. Benichou J,. A review of adjusted estimators of attributable risk. Stat. Methods Med. Res. 2001; 10: 195-216.
29. Rockhill B, Newman B, Weinberg C,. Use and misuse of population attributable fractions. Am. J. Public Health 1998; 88: 15-19.
30. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ,. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
31. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L,. Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-276.
32. Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS, Ekelund J, Illueca M, Beckman O, Sostek MB,. Effects of esomeprazole 40-mg twice daily on asthma: a randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2006; 173: 1091-1097.
33. Kiljander TO, Junghard O, Beckman O, Lind T,. Effect of esomeprazole 40-mg once or twice daily on asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 2010; 181: 1042-1048.
34. American Lung Association Asthma Clinical Research Centers, Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA,. Efficacy of esomeprazole for treatment of poorly controlled asthma. N. Engl. J. Med. 2009; 360: 1487-1499.
35. Writing Committee for the American Lung Association Asthma Clinical Research Centers, Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, Mastronarde JG, et-al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 2012; 307: 373-381.
36. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER,. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301: 2120-2128.
37. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J,. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 2007; 167: 950-955.
38. Johnston N, Wells CW, Samuels TL, Blumin JH,. Pepsin in nonacidic refluxate can damage hypopharyngeal epithelial cells. Ann. Otol. Rhinol. Laryngol. 2009; 118: 677-685.
39. Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Furuta T,. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. Digestion 2012; 85: 9-17.
40. Fraser A, Delaney B, Moayyedi P,. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am. J. Gastroenterol. 2005; 100: 442-452.
41. Mouli VP, Ahuja V,. Questionnaire based gastroesophageal reflux disease (GERD) assessment scales. Indian J. Gastroenterol. 2011; 30: 108-117.